Enter your email address:

Delivered by FeedBurner

Regulator waives off clinical trials, clears Sanofi TB drug

India carries the highest burden of TB with about 2.69 mn cases in
2018. About 40% of the country's population is estimated to have
latent TB infection. The waiver granted to Sanofi's rifapentine, which
is sold under the brand Priftin, is in the public interest, with a
restricted marketing licence to supply the drug only for the
government-run national TB programme.



Post a Comment